한글목차

세계 수막염균 백신 시장 규모는 2024년 31억 6090만 달러에서 2034년까지 연평균 2.5%의 성장률을 나타낼 것으로 예상됩니다.

연구 개발의 어려움 :

백신 도입에는 막대한 R&D가 필요하며, R&D에 영향을 미치는 주요 요인으로는 인프라 부족, 제한된 자금 조달 기회, 원자재 조달 장벽, 운영상의 결함 등이 있습니다. 또한, R&D 비용은 대기업의 경우 관리할 수 있지만, 중소기업의 경우 여러 가지 어려움에 직면하게 됩니다. 또한, 규제 절차가 복잡하고 많은 문서화와 후속 조치가 필요하기 때문에 백신 연구에 더 많은 시간이 소요됩니다. 따라서 연구를 강화하기 위해서는 R&D 프로세스를 간소화할 필요가 있습니다.

세계 수막염균 백신 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 추진 요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter의 Five Forces 분석
• PEST 분석

제4장 수막염균 백신 시장 분석 : 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 다당류 백신
• 결합 백신
• 혼합 백신
• Men-B 백신
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제5장 수막염균 백신 시장 분석 : 혈청군별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 시장 점유율
• A, B, C, Y, W-135 백신
• 혈청군 B 백신
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제6장 수막염균 백신 시장 분석 : 브랜드별

• 주요 조사 결과
• Menactra
• Menveo
• Nimenrix
• Bexsero
• Trumenba
  • 시장 규모 추이와 예측 : 지역별

제7장 수막염균 백신 시장 분석 : 유통 채널별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 시장 점유율
• 병원 약국
• 소매 약국
• 온라인 약국
  • 시장 규모 추이와 예측 : 지역별
  • 시장 점유율 : 지역별

제8장 수막염균 백신 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제9장 북미의 수막염균 백신 시장 분석

제10장 유럽의 수막염균 백신 시장 분석

제11장 아시아태평양의 수막염균 백신 시장 분석

제12장 라틴아메리카의 수막염균 백신 시장 분석

제13장 중동 및 아프리카의 수막염균 백신 시장 분석

제14장 경쟁 구도

• 기업의 시장 점유율 분석
• 주요 비즈니스 전략 분석

제15장 기업 개요

• GSK plc
• BIO-MED
• Hualan Biological Bacterin Co., Ltd.
• Incepta Pharmaceuticals Ltd.
• JN International
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd
• Walvax Biotechnology Co., Ltd.

제16장 결론 및 제안

• Visiongain의 결론
• 참여 기업을 위한 추천 사항

영문목차

The global Meningococcal Vaccines market is estimated at US$3,160.9 million in 2024 and is projected to grow at a CAGR of 2.5% during the forecast period 2024-2034.

The Meningococcal Vaccines Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Difficulties in R&D

Introduction of vaccine requires immense amount of research and development. Key factors that impact R&D include lack of infrastructure, limited funding opportunities, barriers to obtaining raw material, operational insufficiencies. Furthermore, R&D costs can be manageable for large dominant players while small players face various. challenges. Also, regulatory processes are complex and require lot of documentation and follow-up that further adds to time consuming process for vaccine research. Hence, there is a need to streamline R&D process for enhancing research.

What Questions Should You Ask before Buying a Market Research Report?

How is the Meningococcal Vaccines market evolving?

What is driving and restraining the Meningococcal Vaccines market?

How will each Meningococcal Vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?

How will the market shares for each Meningococcal Vaccines submarket develop from 2024 to 2034?

What will be the main driver for the overall market from 2024 to 2034?

Will leading Meningococcal Vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?

How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?

Who are the leading players and what are their prospects over the forecast period?

What are the Meningococcal Vaccines projects for these leading companies?

How will the industry evolve during the period between 2024 and 2034? What are the implications of Meningococcal

Vaccines projects taking place now and over the next 10 years?

Is there a greater need for product commercialisation to further scale the Meningococcal Vaccines market?

Where is the Meningococcal Vaccines market heading and how can you ensure you are at the forefront of the market?

What are the best investment options for new product and service lines?

What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Meningococcal Vaccines market today, and over the next 10 years:

Our 239-page report provides 105 tables, 161 charts and graphs exclusively to you.

The report highlights key lucrative areas in the industry so you can target them - NOW.

It contains in-depth analysis of global, regional and national sales and growth.

It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Meningococcal Vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.

You will find original analyses, with business outlooks and developments.

Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Meningococcal Vaccines prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, "V", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report

Type

Polysaccharide Vaccines

Conjugate Vaccines

Combination Vaccines

Men B Vaccines

Serogroups

A, B, C, Y, W-135 Vaccines

Serogroup B Vaccines

Brands

Menactra

Menveo

Nimenrix

Bexsero

Trumenba

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

MEA

GCC

South Africa

Rest of MEA

The report also includes profiles and for some of the leading companies in the Meningococcal Vaccines Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies profiled in the report

BIO-MED

GSK plc

Hualan Biological Bacterin Co., Ltd.

Incepta Pharmaceuticals Ltd.

JN International

Pfizer Inc.

Sanofi

Serum Institute of India Pvt. Ltd.

Walvax Biotechnology Co., Ltd.

Overall world revenue for Meningococcal Vaccines Market, 2024 to 2034 in terms of value the market will surpass US$3,100.0 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Meningococcal Vaccines Market, 2024 to 2034 report help you?

In summary, our 230+ page report provides you with the following knowledge:

Revenue forecasts to 2034 for Meningococcal Vaccines Market, 2024 to 2034 Market, with forecasts for type, serogroups, brands, and distribution channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.

Revenue forecasts to 2034 for five regional and 20 key national markets - See forecasts for the Meningococcal Vaccines Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Mexico, Brazil, Germany, France, U.K., Italy, China, India, Japan, and Australia among other prominent economies.

Prospects for established firms and those seeking to enter the market - including company profiles for 9 of the major companies involved in the Meningococcal Vaccines Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Meningococcal Vaccines Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Meningococcal Vaccines Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
  • 3.2.2 Market Restraining Factors
  • 3.2.3 Market Opportunities
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat of Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis

4 Meningococcal Vaccines Market Analysis by Type

• 4.1 Key Findings
• 4.2 Type Segment: Market Attractiveness Index
• 4.3 Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 4.4 Polysaccharide vaccines
  • 4.4.1 Polysaccharide Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.4.2 Polysaccharide vaccines Market Share by Region, 2024-2034 (%)
• 4.5 Conjugate vaccines
  • 4.5.1 Conjugate Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.5.2 Conjugate vaccines Market Share by Region, 2024-2034 (%)
• 4.6 Combination vaccines
  • 4.6.1 Combination Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.6.2 Combination Vaccines Market Share by Region, 2024-2034 (%)
• 4.7 Men B vaccines
  • 4.7.1 Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 4.7.2 Men B vaccines Market Share by Region, 2024-2034 (%)

5 Meningococcal Vaccines Market Analysis by Serogroups

• 5.1 Key Findings
• 5.2 Serogroups Segment: Market Attractiveness Index
• 5.3 Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 5.4 Meningococcal Vaccines Market Share by Serogroups, 2024 & 2034
• 5.5 A, B, C, Y, W-135 vaccines
  • 5.5.1 A, B, C, Y, W-135 Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.5.2 A, B, C, Y, W-135 vaccines Market Share by Region, 2024-2034 (%)
• 5.6 Serogroup B vaccines
  • 5.6.1 Serogroup Men B Vaccines Market Forecast by Region, 2024-2034 (US$ Mn)
  • 5.6.2 Serogroup Men B Vaccines Market Share by Region, 2024-2034 (%)

6 Meningococcal Vaccines Market Analysis by Brand

• 6.1 Key Findings
• 6.2 Menactra
  • 6.2.1 Menactra Market Forecast, 2024-2034 (US$ Mn)
• 6.3 Menveo
  • 6.3.1 Menveo Market Forecast, 2024-2034 (US$ Mn)
• 6.4 Nimenrix
  • 6.4.1 Nimenrix Market Forecast, 2024-2034 (US$ Mn)
• 6.5 Bexsero
  • 6.5.1 Bexsero Market Forecast, 2024-2034 (US$ Mn)
• 6.6 Trumenba
  • 6.6.1 Trumenba Market Forecast, 2024-2034 (US$ Mn)

7 Meningococcal Vaccines Market Analysis by Distribution Channel

• 7.1 Key Findings
• 7.2 Distribution Channel Segment: Market Attractiveness Index
• 7.3 Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 7.4 Meningococcal Vaccines Market Share by Distribution Channel, 2024, 2029, 2034
• 7.5 Hospital Pharmacies
  • 7.5.1 Hospital Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.5.2 Hospital Pharmacies Market Share by Region, 2024-2034 (%)
• 7.6 Retail Pharmacies
  • 7.6.1 Retail Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.6.2 Retail Pharmacies Market Share by Region, 2024-2034 (%)
• 7.7 Online Pharmacies
  • 7.7.1 Online Pharmacies Market Forecast by Region, 2024-2034 (US$ Mn)
  • 7.7.2 Online Pharmacies Market Share by Region, 2024-2034 (%)

8 Meningococcal Vaccines Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Meningococcal Vaccines Market Analysis

• 9.1 Key Findings
• 9.2 North America Meningococcal Vaccines Market Attractiveness Index
• 9.3 North America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 9.4 North America Meningococcal Vaccines Market Size Estimation and Forecast by Country
• 9.5 North America Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 9.6 North America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 9.7 North America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 9.8 U.S.
  • 9.8.1 U.S. Meningococcal Vaccines Market by Type
• 9.9 Canada
  • 9.9.1 Canada Meningococcal Vaccines Market by Type

10 Europe Meningococcal Vaccines Market Analysis

• 10.1 Key Findings
• 10.2 Europe Meningococcal Vaccines Market Attractiveness Index
• 10.3 Europe Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 10.4 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Country
• 10.5 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 10.6 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 10.7 Europe Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 10.8 Germany
  • 10.8.1 Germany Meningococcal Vaccines Market by Type
• 10.9 U.K.
  • 10.9.1 U.K. Meningococcal Vaccines Market by Type
• 10.10 France
  • 10.10.1 France Meningococcal Vaccines Market by Type
• 10.11 Italy
  • 10.11.1 Italy Meningococcal Vaccines Market by Type
• 10.12 Spain
  • 10.12.1 Spain Meningococcal Vaccines Market by Type
• 10.13 Rest of Europe
  • 10.13.1 Rest of Europe Meningococcal Vaccines Market by Type

11 Asia Pacific Meningococcal Vaccines Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Meningococcal Vaccines Market Attractiveness Index
• 11.3 Asia Pacific Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 11.4 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 11.6 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 11.7 Asia Pacific Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 11.8 Japan
• 11.9 China
  • 11.9.1 China Meningococcal Vaccines Market by Type
• 11.10 India
  • 11.10.1 India Meningococcal Vaccines Market by Type
• 11.11 South Korea
  • 11.11.1 South Korea Meningococcal Vaccines Market by Type
• 11.12 Australia
  • 11.12.1 Australia Meningococcal Vaccines Market by Type
• 11.13 Rest of APAC
  • 11.13.1 Rest of APAC Meningococcal Vaccines Market by Type

12 Latin America Meningococcal Vaccines Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Meningococcal Vaccines Market Attractiveness Index
• 12.3 Latin America Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 12.4 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Country
• 12.5 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 12.6 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 12.7 Latin America Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 12.8 Brazil
  • 12.8.1 Brazil Meningococcal Vaccines Market by Type
• 12.9 Mexico
• 12.10 Rest of Latin America
  • 12.10.1 Rest of LATAM Meningococcal Vaccines Market by Type

13 MEA Meningococcal Vaccines Market Analysis

• 13.1 Key Findings
• 13.2 MEA Meningococcal Vaccines Market Attractiveness Index
• 13.3 MEA Meningococcal Vaccines Market by Country, 2024, 2029 & 2034 (US$ Mn)
• 13.4 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Country
• 13.5 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Type
• 13.6 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Serogroups
• 13.7 MEA Meningococcal Vaccines Market Size Estimation and Forecast by Distribution Channel
• 13.8 South Africa
  • 13.8.1 South Africa Meningococcal Vaccines Market by Type
• 13.9 GCC
  • 13.9.1 GCC Meningococcal Vaccines Market by Type
• 13.10 Rest of MEA
  • 13.10.1 Rest of MEA Meningococcal Vaccines Market by Type

14 Competitive Landscape

• 14.1 Company Market Share Analysis
• 14.2 Key Business Strategy Analysis

15 Company Profiles

• 15.1 GSK plc
  • 15.1.1 Company Snapshot
  • 15.1.2 Company Overview
  • 15.1.3 Financial Analysis
  • 15.1.4 Product Benchmarking
  • 15.1.5 Pipeline Analysis
  • 15.1.6 Strategic Outlook
• 15.2 BIO-MED
  • 15.2.1 Company Snapshot
  • 15.2.2 Company Overview
  • 15.2.3 Product Benchmarking
• 15.3 Hualan Biological Bacterin Co., Ltd.
  • 15.3.1 Company Snapshot
  • 15.3.2 Company Overview
  • 15.3.3 Product Benchmarking
• 15.4 Incepta Pharmaceuticals Ltd.
  • 15.4.1 Company Snapshot
  • 15.4.2 Company Overview
  • 15.4.3 Product Benchmarking
• 15.5 JN International
  • 15.5.1 Company Snapshot
  • 15.5.2 Company Overview
  • 15.5.3 Product Benchmarking
• 15.6 Pfizer Inc.
  • 15.6.1 Company Snapshot
  • 15.6.2 Company Overview
  • 15.6.3 Financial Analysis
  • 15.6.4 Product Benchmarking
  • 15.6.5 Strategic Outlook
• 15.7 Sanofi
  • 15.7.1 Company Snapshot
  • 15.7.2 Company Overview
  • 15.7.3 Financial Analysis
  • 15.7.4 Product Benchmarking
  • 15.7.5 Pipeline Analysis
  • 15.7.6 Strategic Outlook
• 15.8 Serum Institute of India Pvt. Ltd
  • 15.8.1 Company Snapshot
  • 15.8.2 Company Overview
  • 15.8.3 Product Benchmarking
  • 15.8.4 Strategic Outlook
• 15.9 Walvax Biotechnology Co., Ltd.
  • 15.9.1 Company Snapshot
  • 15.9.2 Company Overview
  • 15.9.3 Product Benchmarking
  • 15.9.4 Pipeline Analysis

16 Conclusion and Recommendations

• 16.1 Concluding Remarks from Visiongain
• 16.2 Recommendations for Market Players